Bana Jobe

Every year, some 40 million Americans get at least one spot on their skin that looks discolored, scaly, or rough. They have what's called actinic keratosis, or AK, and it's among the most common skin problems that Dermatologists see, according to the American Academy of Dermatologists.

Few policy topics in cardiology have been argued as much as the question of whether clinicians should screen for asymptomatic or paroxysmal Afib. Undoubtedly, diagnosing Afib earlier rather than later is better, as the condition increases stroke risk by five times, and interventions using oral anticoagulants can reduce that risk by 65%. Yet screening recommendations in general populations must account for other factors beyond outcomes alone, from patient anxiety and feasibility to healthcare costs.

For all it does to help the skin, many people still don't know how to apply sunscreen the right way—and improper use can shortchange you of its benefits. But by following these best practices, you'll be well on your way to improving your skin health.

People often talk about art and science as if they're at odds, but are they? Joseph Regan, Ph.D., doesn't think so. A biologist and artist himself, Dr. Regan says creativity informs his work in the lab and vice versa. Whether he's studying complex 3D organoids or making cell images pop with color for a journal cover, the collision of both art and science is what he finds most inspiring.

Beno Freedman, Ph.D., says that the human system is a "black box"—researchers have no way of knowing what's going on inside until they get in and see it up close. That's why, Freedman says, organoids have had a profound effect on our understanding of human biology—particularly in his field, regenerative medicine.

Racial reckoning calls for uncomfortable conversations and difficult introspection. But before anyone can be anti-racist, they have to understand the pernicious effects of bias in STEM research. It starts with listening—and continues with action.

The surge of pandemic-related activity, along with growth in bioproduction and other segments of the life sciences industry, has brought with it an unprecedented demand for supplies. Here's what Corning's doing to address the situation.

Lung organoids are a modern marvel—and perhaps one of the most remarkable things about them is that they evolved just in time to help with a global pandemic.

Not everyone agrees with a universal ECG requirement for student athletes, particularly in the United States. But now, as the long-term cardiac implications of COVID-19 become more understood, many prominent sports groups are requiring ECG testing, and the evergreen debate has been renewed at the local and national levels.

As millions of Americans confront economic, social, and emotional stressors tied to the COVID-19 pandemic, cardiologists are wondering what toll all of that stress is taking on patients' heart health—particularly regarding their risk of broken heart syndrome.

The pre-launch phase of the drug commercialization journey is a mission-critical time that weighs heavily on product and patient outcomes. Manufacturers invest in and align on the building blocks of a successful therapeutic debut during this pre-market period—developing the unique value proposition, defining distribution channel strategy, and designing patient support services. But how do you find the right partner to help?

Regardless of your lab's size or scale, there will come a time when you need a customized solution for your media, sera, or reagents. Off-the-shelf lab products are great for many production needs, but scientists often find themselves searching for tailor-made options when the standard catalog doesn't quite fit the project. But there's a catch: With customization comes many considerations. Researchers who thoughtfully explore each one will be best equipped to reap the benefits of customization with minimal risk, cost, and resources.

Considering everything it takes to scale up gene therapy — the platforms, the media, the surfaces, the vessels, the equipment — developing viral vector production processes comes with many challenges. It's no surprise, then, that labs sometimes miss a few things when scaling their gene therapeutics up or out, and those oversights can set projects back. These are common pitfalls — but most researchers don't realize that they're problematic until it's far too late.

Any lab of any size, with the help of the right partners, can customize its process so that it can incorporate future innovations — and in vaccine production, you never know when that next big thing could come along. By following these tips, you can scale your processes and goals without locking yourself into a legacy setup.

For the Einstein Lab and others like it, it's about the love — the love of doing what's right, and the love of science. And those aren't mutually exclusive.